Oyster Therapeutics Series A

London-based Oyster Therapeutics, formerly known as Kesmalea Therapeutics, has closed a $60 million Series A-2 follow-on financing round. The investment represents a milestone extension to the biotechnology company's existing Series A capitalization following its recent corporate rebranding. While specific operational metrics, participating investors, and capital deployment plans were not disclosed in the announcement, the multi-million-dollar tranche marks a substantial capital expansion for the UK-based firm.